Aequus provides an update on the delay in filing annual financial statements

Aequus provides an update on the delay in filing annual financial statements

Due to delays in the Company’s audit method and getting timely responses to its audit requests from third parties, the Annual Disclosure was filed late. The Company’s management is working carefully to resolve the different challenges in order to complete the Annual Disclosure as soon as possible.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”) announces that the filing of its audited annual financial statements and management’s discussion and analysis relating to the Annual Financial Statements (collectively, the “Annual Disclosure”) will be postponed beyond the May 2, 2022 filing deadline.

The Company fully expects to file the Annual Disclosure on or before Friday, May 6, 2022, and intends to provide updates on further developments in respect of this matter promptly following their occurrence.

About Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF ) is a growing specialty pharmaceutical company focused on developing and commercializing high quality, differentiated products. Aequus has grown its sales and marketing efforts to include several commercial products in ophthalmology and transplant. Aequus plans to build on its Canadian commercial platform through the launch of additional products that are either created internally or brought in through an acquisition or license; remaining focused on highly specialized therapeutic areas.


Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more
We will be happy to hear your thoughts

Leave a reply

Compsmag - Latest News In Tech and Business